Palacios Eda, Dallman Rebecca, Muñoz Maribel, Hurtado Rocio, Chalco Katiuska, Guerra Dalia, Mestanza Lorena, Llaro Karim, Bonilla Cesar, Drobac Peter, Bayona Jaime, Lygizos Melissa, Anger Holly, Shin Sonya
Socios En Salud, Sucursal Peru, Carabayllo, Lima, Peru.
Clin Infect Dis. 2009 May 15;48(10):1413-9. doi: 10.1086/598191.
Multidrug-resistant tuberculosis (MDR-TB) disproportionately affects young adults, including women of childbearing age; however, treatment of MDR-TB during pregnancy is still controversial. This study looks at the treatment and pregnancy outcomes in a cohort of women who were treated for MDR-TB during pregnancy during a period of 10 years.
A retrospective case study was performed using a standardized data collection form and data from 3 ranked sources of patient records. All 38 participants were treated during pregnancy with individualized regimens that included second-line TB medications. We examined the frequency of favorable and adverse outcomes with regard to disease and pregnancy.
After completion of MDR-TB treatment, 61% of the women were cured, 13% had died, 13% had defaulted, 5% remained in treatment, and 5% had experienced treatment failure. Four of the women experienced clinical deterioration of TB during pregnancy. Five of the pregnancies terminated in spontaneous abortions, and 1 child was stillborn. Among the living newborns, 3 were born with low birth weight, 1 was born prematurely, and 1 had fetal distress.
The rates of success in treating MDR-TB in our cohort are comparable to those of other MDR-TB treatment programs in Peru. The birth outcomes of our cohort are similar to those among the general Peru population. Therefore, we advocate that a woman should be given the option to continue treatment of MDR-TB rather than terminating pregnancy or discontinuing MDR-TB treatment.
耐多药结核病(MDR-TB)对年轻人,包括育龄妇女影响尤为严重;然而,孕期耐多药结核病的治疗仍存在争议。本研究观察了一组在10年期间接受孕期耐多药结核病治疗的女性的治疗情况及妊娠结局。
采用标准化数据收集表和来自3个排名靠前的患者记录来源的数据进行回顾性病例研究。所有38名参与者在孕期接受了包含二线抗结核药物的个体化治疗方案。我们检查了疾病和妊娠方面的有利和不利结局的频率。
耐多药结核病治疗完成后,61%的女性治愈,13%死亡,13%失访,5%仍在治疗中,5%治疗失败。4名女性在孕期出现结核病临床恶化。5次妊娠以自然流产告终,1名婴儿死产。在存活的新生儿中,3名出生时体重低,1名早产,1名出现胎儿窘迫。
我们队列中耐多药结核病的治疗成功率与秘鲁其他耐多药结核病治疗项目相当。我们队列的出生结局与秘鲁普通人群相似。因此,我们主张应给予女性继续接受耐多药结核病治疗的选择,而不是终止妊娠或停止耐多药结核病治疗。